Standard Therapy in Cardiac Amyloidosis: What is Known, What is "Gray".
Heart Fail Clin
; 20(3): 325-331, 2024 Jul.
Article
en En
| MEDLINE
| ID: mdl-38844303
ABSTRACT
Amyloidosis is a systemic disease due to the accumulation of misfolded amyloid fibrils that damage the heart and worsen the prognosis. Heart failure (HF), a condition frequently linked with an advanced stage of this disease, is the most prevalent clinical manifestation that leads to its diagnosis. However, due to the growing awareness of the occurrence of cardiac amyloidosis (CA), it is now possible to perform an early diagnosis and have a positive impact on its natural course. This study aims to highlight the most compelling issues concerning patients' clinical management with HF and CA.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Insuficiencia Cardíaca
/
Amiloidosis
/
Cardiomiopatías
Límite:
Humans
Idioma:
En
Revista:
Heart Fail Clin
Año:
2024
Tipo del documento:
Article